News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Argenes Initiates Phase I Clinical Study of ARG098 (anti-Fas IgM monoclonal antibody), a Novel Therapeutics for Rheumatoid Arthritis, in Europe


10/5/2007 9:20:30 AM

Tokyo, Oct 5, 2007 (JCN Newswire) - Argenes, Inc. announce today that it has started Phase I clinical study of the novel anti-rheumatoid arthritis (RA) agent ARG098 in patients with RA in Belgium and has administered to the first patient. The clinical study intends to evaluate the safety and tolerability of ARG098 into the knee joint cavity of patients with RA and examine its efficacy and pharmacokinetics.

Read at BioSpace.com

comments powered by Disqus
Argenes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES